TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo

STAT3 operates in both cancer cells and tumor-associated immune cells to promote cancer progression. As a transcription factor, it is a highly desirable but difficult target for pharmacologic inhibition. We have recently shown that the TLR9 agonists CpG oligonucleotides can be used for targeted siRN...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zhang, Qifang, Hossain, Dewan Md Sakib, Nechaev, Sergey, Kozlowska, Anna, Zhang, Wang, Liu, Yong, Kowolik, Claudia M., Swiderski, Piotr, Rossi, John J., Forman, Stephen, Pal, Sumanta, Bhatia, Ravi, Raubitschek, Andrew, Yu, Hua, Kortylewski, Marcin
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2013
Matèries:
Gene Therapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3578952/
https://ncbi.nlm.nih.gov/pubmed/23287859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-07-442590
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars